This suggests that hematologists adhere to guidelines recommending molecularly targeted therapy, particularly BTKi, for patients with CLL at high risk in terms of prognosis, such as those with 17p deletion or TP53 mutation [4]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.